drugset / Trial / NCT00153842
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer
Phase 1/2
Terminated
33 enrolled
Dartmouth-Hitchcock Medical Center
Bristol-Myers Squibb · collabLigand Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to patients with stage IIIB and IV non-small cell lung cancer. This study will also evaluate the preliminary efficacy (Phase II component) of bexarotene oral capsules in combination with the weekly Taxol® schedule and carboplatin in these patients.
Timeline
- Start
- 2001-08
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 300 mg | Oral |
| Subject | Bexarotene | Small molecule | 400 mg | Oral |